Antigens, CD20
"Antigens, CD20" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
Descriptor ID |
D018951
|
MeSH Number(s) |
D23.050.301.264.035.120 D23.050.301.264.051.120 D23.101.100.110.120 D23.101.100.150.120
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antigens, CD20".
- Chemicals and Drugs [D]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Antigens, CD20 [D23.050.301.264.035.120]
- Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
- Antigens, CD20 [D23.050.301.264.051.120]
- Biological Markers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Antigens, CD20 [D23.101.100.110.120]
- Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
- Antigens, CD20 [D23.101.100.150.120]
Below are MeSH descriptors whose meaning is more specific than "Antigens, CD20".
This graph shows the total number of publications written about "Antigens, CD20" by people in this website by year, and whether "Antigens, CD20" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 1 | 1 | 2003 | 0 | 1 | 1 | 2011 | 0 | 1 | 1 | 2013 | 0 | 1 | 1 | 2018 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antigens, CD20" by people in Profiles.
-
Kanis MJ, Zielenbach M, Karmali R, Peevey J, Blanco LZ, Horowitz JM, Lurain JR. Painless Vulvar Masses as Initial Manifestation of Marginal Zone Lymphoma. J Low Genit Tract Dis. 2018 Jan; 22(1):82-84.
-
Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, Bodria M, Caridi G, Wei C, Belingheri M, Ghio L, Merscher-Gomez S, Edefonti A, Pasini A, Montini G, Murtas C, Wang X, Muruve D, Vaglio A, Martorana D, Pani A, Scolari F, Reiser J, Ghiggeri GM. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int. 2013 Nov; 84(5):1025-33.
-
Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011 Jun 01; 3(85):85ra46.
-
Rao R, Vugman G, Leslie WT, Loew J, Venugopal P. Lymphomatoid granulomatosis treated with rituximab and chemotherapy. Clin Adv Hematol Oncol. 2003 Nov; 1(11):658-60; discussion 660.
-
Kim D, Hur DY, Kim YS, Lee K, Lee Y, Cho D, Kang JS, Kim YI, Hahm E, Yang Y, Yoon S, Kim S, Lee WB, Park HY, Kim YB, Hwang YI, Chang KY, Lee WJ. CM1 ligation initiates apoptosis in a caspase 8-dependent manner in Ramos cells and in a mitochondria-controlled manner in Raji cells. Hum Immunol. 2002 Jul; 63(7):576-87.
-
Coon JS, Wang YZ, Bines SD, Markham PN, Chong AS, Gebel HM. Multidrug resistance activity in human lymphocytes. Hum Immunol. 1991 Oct; 32(2):134-40.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|